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INSULIN AND DETEMIR INSULIN IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS IN MEXICO
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Mc Gregor Sánchez Navarro. IMSS, Mexico City, Mexico
OBJECTIVES: To perform a comparative study comparing annual costs linked to the 
treatment with Insulin Glargine (IG) and Insulin Detemir (ID) from the Mexican private 
market perspective. METHODS: Clinical data related to each treatment derives, from 
a study performed by Rosenstock et al (2006): a 52-week open-label, parallel, multi-
national trial, which compares efﬁcacy and safety of IG and ID. This trial demonstrated 
no difference in terms of HbA1c and tolerability. However, this study has shown that 
patients treated with IG required a lower total dose of insulin, and that 55% of patients 
treated ended up the study with two injections per day in order to reach control. The 
cost of each insulin regimen was calculating using the unit cost of insulins, needles 
and blood glucose tests. Costs calculations referred to year 2008 and unit costs were 
derived from public tenders databases and published tariffs. A sensitivity analysis was 
performed using a Monte Carlo simulation. RESULTS: Overall, patients treated with 
ID required 59% more insulin than those treated with IG. In patients with DM2, 
management with IG has lower total costs than IG, which allows savings of US$474.7 
per patient-year. Savings were related to the costs of total insulin, needles and blood 
glucose tests. Sensitivity analysis showed a range of savings between US$288 and 
US$661 in a 95% conﬁdence interval. CONCLUSIONS: For patients with DM2, 
treatment with Insulin Glargine is an efﬁcacious and cost-saving option compared with 
ID, because Insulin Glargine is associated with a comparable efﬁcacy and tolerability 
and lower annual total costs, allowing savings of up to US$474.7 per patient-year 
which represents 35.2% of the overall cost of insulin per patient-year.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes Studies
PDB12
ADHERENCE TO GLIMEPIRIDE FOR TYPE 2 DIABETICS IN COLOMBIA
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OBJECTIVES: To assess adherence and main causes of discontinuation in diabetic 
patients who started treatment with glimepiride in real-life settings in Colombia 
METHODS: A cohort of type 2 diabetic patients from 66 centers, who started treat-
ment with glimepiride 4 mg were followed for 1 year. Physical examinations and lab 
tests were performed according to clinical practice every 3–4 months. Quality of life 
was assessed (SF-8) at baseline and the end of follow-up. RESULTS: 444 patients were 
included; 43.1% female; mean age: 59.9 o 12.5 for females and 58.0 o 13.4 years for 
men. Most patients had higher education level(73%), 28.5% were retired, and 60% 
were paying health care out-of-pocket. The most common comorbidity was hyperten-
sion (64.1%). Baseline BMI and abdominal circumference: 27.6 kg/m2 and 97.9 cm 
for males and 27.4 kg/m2 and 93.2 for females. Mean HbA1c levels and fasting blood 
glucose: 8.3% and 199.88 mg/dl. Just 4% had additional antidiabetic medications. 
After one year of follow-up, information on 82% (n  367) of the patients was avail-
able. 75% (n  332)continued the treatment with glimepiride. The main reason to 
discontinue the treatment was forgetfulness. All patients who continued the treatment 
improved their glicemic control with signiﬁcant changes (p  0.05) in mean HbA1c 
(6.57%) and fasting blood glucose (109 mg/dl). Characteristics associated with con-
tinuation of treatment, were higher education, higher socioeconomic status, better 
insurance coverage, and healthy habits. Patients also reported improvement in their 
quality of life at the end of the follow-up. Only 1 patient reported an adverse event 
not related with the treatment(hip fracture). No serious adverse events or hypoglyce-
mic events requiring medical attention were reported. CONCLUSIONS: In the ﬁrst 
year of treatment with glimepiride most patients continue the therapy, and the main 
reason for discontinuation was forgetfulness. Patients who are adherent to their anti-
diabetic therapy, with glimepiride in Colombia, improve glicemic control and improve 
their self-rated health status.
DIABETES/ENDOCRINE DISORDERS – Health Care Use & Policy Studies
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ENCUESTA SOBRE LAS PRACTICAS DE UTILIZACION Y TITULACION 
DE INSULINA EN LATINOAMERICA
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OBJECTIVES: To determine current preferences in the use and titration algorithms 
for insulin, in physicians currently prescribing glargine for adult diabetic patients in 
Latin America. METHODS: A cross-sectional survey was performed to physicians 
randomly selected based on their country and specialty. The survey collected informa-
tion about the practice of the physician, use and preference of insulin and titration 
algorithm for glargine in type 1 diabetics, and in type 2 diabetics, between September 
and November 2007. RESULTS: A total of 649 physicians from 12 countries in Latin 
America were included in the analysis. Almost one third of glargine prescribers were 
endrocrinologists, although the distribution by specialty was variable across countries. 
For people with type 1 diabetes, physicians preferred the use of long-acting insulin 
(53.8%). Only a few physicians preferred the use of premixed insulin (16.3%). Almost 
half of the physicians surveyed reported the use of insulin analogs for combinations 
in these patients. In people with type 2 diabetes, up to 48% of physicians prefer 
intermediate insulin alone or combined with rapid-acting insulin analogs (31%), or 
short-acting insulin (18%). There is more homogeneity in the treatment preference 
across specialties for these patients. Only 20% reported use of premixed insulin. A 
simple physician driven weekly dose adjustment algorithm was preferred for the titra-
tion of insulin glargine (37%). CONCLUSIONS: The use of insulin analogs and 
intensive titration algorithms is more frequent in physicians that treat people with type 
1 diabetes; on the other hand, the use of intermediate-acting insulin and conventional 
management is more frequent in people with type 2 diabetes. Simple weekly dose 
adjustment algorithms for titration of glargine with low patient participation are most 
often used in Latin America.
PDB14
UTILIZACIÓN DE RECURSOS Y GASTOS EN SALUD DE PERSONAS 
CON DIABETES EN ARGENTINA. UN ANÁLISIS DESCRIPTIVO DE LA 
ENCUESTA NACIONAL DE UTILIZACIÓN Y GASTOS EN SERVICIOS  
DE SALUD
Gonzalez L, Caporale JE, Elgart J, Pﬁrter G, Gagliardino JJ
CENEXA—Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
OBJECTIVOS: Realizar un análisis descriptivo de la encuesta de utilización y gastos 
en salud para personas con diabetes y veriﬁcar la existencia de desigualdades en 
estos indicadores según distintas dimensiones demográﬁcas y socioeconómicas. 
 METODOLOGÍAS: Análisis estadístico descriptivo e inferencial: diferencias en 
medias y proporciones se veriﬁcaron mediante Student, ANOVA y Chi2. RESULTA-
DOS: Identiﬁcamos un 10.2% de diabéticos (N  1,258,892), cifra similar a la preva-
lencia por autoreporte encontrada en la Encuesta Nacional de Factores de Riesgo 
(ENFR). La proporción de hombres y la edad promedio fue mayor a las registradas 
en la población sin DM [64.7% vs. 48.3%; 53.2 o 22.9 vs. 39.3 o 21.4]. El 75.7% 
de los diabéticos tenía seguro de salud (Seguridad Social el 83.3%). Entre estas per-
sonas, en los últimos 30 días: 1) el 75.8% realizó al menos una consulta clínica; 2) el 
35.9% se realizó al menos un análisis o práctica; 3) el 1.75% consultó por salud 
mental; 4) el 92.1% ha usado y el 69.7% comprado, algún medicamento; y 5) el 5.2% 
se interno en el último año. Algunas de estas tasas de uso fueron signiﬁcativamente 
diferentes según el tipo de cobertura médica (p  0.01). Entre los diabéticos, el gasto 
medio para muchos de los conceptos fue signiﬁcativamente menor (p  0.01) para los 
aﬁliados a la Seguridad Social respecto de otros tipos de cobertura. Asimismo, los 
diabéticos registraron mayores gastos medios de bolsillo en medicamentos (AR$ 72.3 
vs AR$ 42.7) e internaciones (AR$ 320.0 vs AR$ 144.5) que los no DM. CONCLU-
SIONES: Este estudio es el primer análisis descriptivo poblacional que investiga la 
interrelación de variables socioeconómicas y demográﬁcas con utilización y gasto de 
bolsillo en personas con DM de Argentina. Estos resultados son útiles para la pro-
gramación, elaboración y evaluación de programas de atención y prevención de dia-
betes en el sistema de salud argentino.
GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
PGI1
A STRONG NONLINEAR RELATIONSHIP BETWEEN ADHERENCE WITH 
DRUG THERAPY AND CONTINUOUS RISK FACTORS IN PPI USERS
Pedan A, Lu J, Varasteh LT
Adheris, Inc, Burlington, MA, USA
OBJECTIVES: Current understanding of the impact of continuous predictors of 
patient adherence, such as copayment, age, and number of reﬁlls prescribed with drug 
therapy is largely based on the results of parametric multivariate regression analyses. 
In such a regression, the copayment is usually introduced as a linear effect of continu-
ous risk factors or as a multi- level categorical variable. To assess the potential impact 
of the a priori assumption of linearity or categorization on the results of parametric 
analyses, the authors completed an analysis using an assumption-free nonparametric 
modeling approach. METHODS: The data set included 42,221 patients new to PPI 
therapy. The outcome variable was deﬁned as the total number of 30-day reﬁlls that 
patients obtained during a 6-month follow-up period. The effects of copayment, age, 
and number of reﬁlls prescribed on adherence, adjusted for other common risk factors, 
were estimated using a smoothing spline method available in the generalized additive 
model extension of the Poisson regression. RESULTS: The generalized additive model 
ﬁts the data signiﬁcantly (p  0.01) better than the parametric Poisson regression. 
The authors conclude that there are strong and practically important nonlinear 
 relationships between adherence and analyzed continuous independent predictors. 
CONCLUSIONS: The linear approximation or categorization of these effects inherent 
in parametric models may result in biased estimates of the effects of adherence.
